ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Clinical trials for ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for lung cancer: AstraZeneca trials combo therapies
Disease control Recruiting nowThis study tests new combinations of cancer drugs in people with advanced or metastatic non-small cell lung cancer. The goal is to find safer and more effective treatments. About 152 adults will take part, and the study is currently recruiting.
Matched conditions: ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 06:04 UTC
-
New hope for advanced lung cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug (SHR-A2102) combined with another drug (adebrelimab) for people with advanced or metastatic non-small cell lung cancer. The goal is to find the safest dose and see if the treatment shrinks tumors. About 248 adults aged 18-70 will take part.
Matched conditions: ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:02 UTC
-
New hope for lung cancer: novel drug combos enter phase 2 trial
Disease control Recruiting nowThis clinical trial is testing whether new combinations of drugs work better than standard treatments for people with non-small-cell lung cancer. The study includes patients with advanced cancer that has spread, as well as those with earlier-stage tumors that can be removed by su…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New lung cancer cocktail aims to outperform current standard
Disease control Recruiting nowThis study tests whether a new combination of drugs (SHR-8068, adebrelimab, and chemotherapy) works better than the current standard treatment (tislelizumab plus chemotherapy) for people with advanced or metastatic non-small cell lung cancer who have not had prior treatment. Abou…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:45 UTC